356 related articles for article (PubMed ID: 11037965)
1. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
Weiner GJ
J Leukoc Biol; 2000 Oct; 68(4):455-63. PubMed ID: 11037965
[TBL] [Abstract][Full Text] [Related]
2. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
3. Use of CpG oligonucleotides in treatment of asthma and allergic disease.
Fonseca DE; Kline JN
Adv Drug Deliv Rev; 2009 Mar; 61(3):256-62. PubMed ID: 19167442
[TBL] [Abstract][Full Text] [Related]
4. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides.
Mutwiri GK; Nichani AK; Babiuk S; Babiuk LA
J Control Release; 2004 May; 97(1):1-17. PubMed ID: 15147800
[TBL] [Abstract][Full Text] [Related]
5. CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells.
Marschner A; Rothenfusser S; Hornung V; Prell D; Krug A; Kerkmann M; Wellisch D; Poeck H; Greinacher A; Giese T; Endres S; Hartmann G
Eur J Immunol; 2005 Aug; 35(8):2347-57. PubMed ID: 16025562
[TBL] [Abstract][Full Text] [Related]
6. Alpha 2-macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism.
Anderson RB; Cianciolo GJ; Kennedy MN; Pizzo SV
J Leukoc Biol; 2008 Feb; 83(2):381-92. PubMed ID: 17967834
[TBL] [Abstract][Full Text] [Related]
7. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides.
Mutwiri G; van Drunen Littel-van den Hurk S; Babiuk LA
Adv Drug Deliv Rev; 2009 Mar; 61(3):226-32. PubMed ID: 19162103
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant properties of CpG oligonucleotides in primates.
Verthelyi D
Methods Mol Med; 2006; 127():139-58. PubMed ID: 16988453
[TBL] [Abstract][Full Text] [Related]
9. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy.
Jahrsdörfer B; Weiner GJ
Curr Opin Investig Drugs; 2003 Jun; 4(6):686-90. PubMed ID: 12901226
[TBL] [Abstract][Full Text] [Related]
10. The potential of CpG oligodeoxynucleotides as mucosal adjuvants.
McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
Crit Rev Immunol; 2001; 21(1-3):103-20. PubMed ID: 11642598
[TBL] [Abstract][Full Text] [Related]
11. Role of invariant NK T lymphocytes in immune responses to CpG oligodeoxynucleotides.
Paget C; Bialecki E; Fontaine J; Vendeville C; Mallevaey T; Faveeuw C; Trottein F
J Immunol; 2009 Feb; 182(4):1846-53. PubMed ID: 19201836
[TBL] [Abstract][Full Text] [Related]
12. T cell-dependent protective effects of CpG motifs of bacterial DNA in experimental colitis are mediated by CD11c+ dendritic cells.
Hofmann C; Dunger N; Grunwald N; Hämmerling GJ; Hoffmann P; Schölmerich J; Falk W; Obermeier F
Gut; 2010 Oct; 59(10):1347-54. PubMed ID: 20732920
[TBL] [Abstract][Full Text] [Related]
13. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
Tewary P; Sukumaran B; Saxena S; Madhubala R
Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
[TBL] [Abstract][Full Text] [Related]
14. Synthetic innate defence regulator peptide enhances in vivo immunostimulatory effects of CpG-ODN in newborn piglets.
Cao D; Li H; Jiang Z; Xu C; Cheng Q; Yang Z; Cao G; Zhang L
Vaccine; 2010 Aug; 28(37):6006-13. PubMed ID: 20637306
[TBL] [Abstract][Full Text] [Related]
15. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.
Klinman DM; Klaschik S; Sato T; Tross D
Adv Drug Deliv Rev; 2009 Mar; 61(3):248-55. PubMed ID: 19272313
[TBL] [Abstract][Full Text] [Related]
16. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice.
Nyström-Asklin J; Adamsson J; Harandi AM
Scand J Immunol; 2008 May; 67(5):431-40. PubMed ID: 18298617
[TBL] [Abstract][Full Text] [Related]
17. CpG motifs as possible adjuvants for the treatment of allergic diseases.
Bohle B
Int Arch Allergy Immunol; 2002 Nov; 129(3):198-203. PubMed ID: 12444316
[TBL] [Abstract][Full Text] [Related]
18. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
19. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
[TBL] [Abstract][Full Text] [Related]
20. Immunostimulatory effects of plasmid DNA and synthetic oligodeoxynucleotides.
Zelenay S; Elías F; Fló J
Eur J Immunol; 2003 May; 33(5):1382-92. PubMed ID: 12731065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]